Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients

Daniel J. Birmingham, Xiao Ping Shen, Judith A. Hartman, John J. Dillon, Lee A. Hebert

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

There are multiple lines of evidence suggesting that human recombinant erythropoietin (rEPO) could influence immune responses by direct effects of rEPO on T or B cells. The present study tested this hypothesis by measuring antibody responses after immunization to tetanus toxoid (TT, a T cell dependent antigen or pneumococcal capsular polysaccharide antigen (PA, a T cell independent antigen). The patients chosen for this prospective study were chronic hemodialysis patients receiving chronic rEPO therapy, and a comparable group of chronic hemodialysis patients not receiving rEPO therapy. We found that the patients immunized with PA and receiving rEPO therapy (N = 15) had IgG anti-PA responses comparable to that of those not receiving rEPO therapy (N = 15). In contrast, in the patients immunized with TT, those receiving rEPO (N = 15) developed significantly higher IgG anti- TT levels than those not receiving rEPO (N = 14) (time-group interaction P =0.005). The peak difference between these groups wits at two weeks, where the rEPO-treated patients developed a 4.1-fold mean increase in IgG anti-TT level and those not receiving rEPO developed only a 1.4-fold mean increase in IgG anti-TT level (P < 0.01). The difference in immune response to TT in the rEPO compared to the non-rEPO-treated patients could not be explained by differences between the groups in any of the parameters measured at baseline or during the post-immunization period. In conclusion, rEPO therapy increased immune response to TT but not PA, which suggests that rEPO enhances immune response to T cell dependent antigens.

Original languageEnglish (US)
Pages (from-to)543-549
Number of pages7
JournalKidney International
Volume50
Issue number2
StatePublished - 1996
Externally publishedYes

Fingerprint

Erythropoietin
Antibody Formation
Renal Dialysis
Immunization
Therapeutics
T-Lymphocytes
Antigens
T Independent Antigens
Tetanus Toxoid
Wit and Humor
Polysaccharides
B-Lymphocytes

ASJC Scopus subject areas

  • Nephrology

Cite this

Birmingham, D. J., Shen, X. P., Hartman, J. A., Dillon, J. J., & Hebert, L. A. (1996). Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. Kidney International, 50(2), 543-549.

Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. / Birmingham, Daniel J.; Shen, Xiao Ping; Hartman, Judith A.; Dillon, John J.; Hebert, Lee A.

In: Kidney International, Vol. 50, No. 2, 1996, p. 543-549.

Research output: Contribution to journalArticle

Birmingham, DJ, Shen, XP, Hartman, JA, Dillon, JJ & Hebert, LA 1996, 'Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients', Kidney International, vol. 50, no. 2, pp. 543-549.
Birmingham, Daniel J. ; Shen, Xiao Ping ; Hartman, Judith A. ; Dillon, John J. ; Hebert, Lee A. / Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. In: Kidney International. 1996 ; Vol. 50, No. 2. pp. 543-549.
@article{a7604e4cde954daf883f90792b5b2d2a,
title = "Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients",
abstract = "There are multiple lines of evidence suggesting that human recombinant erythropoietin (rEPO) could influence immune responses by direct effects of rEPO on T or B cells. The present study tested this hypothesis by measuring antibody responses after immunization to tetanus toxoid (TT, a T cell dependent antigen or pneumococcal capsular polysaccharide antigen (PA, a T cell independent antigen). The patients chosen for this prospective study were chronic hemodialysis patients receiving chronic rEPO therapy, and a comparable group of chronic hemodialysis patients not receiving rEPO therapy. We found that the patients immunized with PA and receiving rEPO therapy (N = 15) had IgG anti-PA responses comparable to that of those not receiving rEPO therapy (N = 15). In contrast, in the patients immunized with TT, those receiving rEPO (N = 15) developed significantly higher IgG anti- TT levels than those not receiving rEPO (N = 14) (time-group interaction P =0.005). The peak difference between these groups wits at two weeks, where the rEPO-treated patients developed a 4.1-fold mean increase in IgG anti-TT level and those not receiving rEPO developed only a 1.4-fold mean increase in IgG anti-TT level (P < 0.01). The difference in immune response to TT in the rEPO compared to the non-rEPO-treated patients could not be explained by differences between the groups in any of the parameters measured at baseline or during the post-immunization period. In conclusion, rEPO therapy increased immune response to TT but not PA, which suggests that rEPO enhances immune response to T cell dependent antigens.",
author = "Birmingham, {Daniel J.} and Shen, {Xiao Ping} and Hartman, {Judith A.} and Dillon, {John J.} and Hebert, {Lee A.}",
year = "1996",
language = "English (US)",
volume = "50",
pages = "543--549",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients

AU - Birmingham, Daniel J.

AU - Shen, Xiao Ping

AU - Hartman, Judith A.

AU - Dillon, John J.

AU - Hebert, Lee A.

PY - 1996

Y1 - 1996

N2 - There are multiple lines of evidence suggesting that human recombinant erythropoietin (rEPO) could influence immune responses by direct effects of rEPO on T or B cells. The present study tested this hypothesis by measuring antibody responses after immunization to tetanus toxoid (TT, a T cell dependent antigen or pneumococcal capsular polysaccharide antigen (PA, a T cell independent antigen). The patients chosen for this prospective study were chronic hemodialysis patients receiving chronic rEPO therapy, and a comparable group of chronic hemodialysis patients not receiving rEPO therapy. We found that the patients immunized with PA and receiving rEPO therapy (N = 15) had IgG anti-PA responses comparable to that of those not receiving rEPO therapy (N = 15). In contrast, in the patients immunized with TT, those receiving rEPO (N = 15) developed significantly higher IgG anti- TT levels than those not receiving rEPO (N = 14) (time-group interaction P =0.005). The peak difference between these groups wits at two weeks, where the rEPO-treated patients developed a 4.1-fold mean increase in IgG anti-TT level and those not receiving rEPO developed only a 1.4-fold mean increase in IgG anti-TT level (P < 0.01). The difference in immune response to TT in the rEPO compared to the non-rEPO-treated patients could not be explained by differences between the groups in any of the parameters measured at baseline or during the post-immunization period. In conclusion, rEPO therapy increased immune response to TT but not PA, which suggests that rEPO enhances immune response to T cell dependent antigens.

AB - There are multiple lines of evidence suggesting that human recombinant erythropoietin (rEPO) could influence immune responses by direct effects of rEPO on T or B cells. The present study tested this hypothesis by measuring antibody responses after immunization to tetanus toxoid (TT, a T cell dependent antigen or pneumococcal capsular polysaccharide antigen (PA, a T cell independent antigen). The patients chosen for this prospective study were chronic hemodialysis patients receiving chronic rEPO therapy, and a comparable group of chronic hemodialysis patients not receiving rEPO therapy. We found that the patients immunized with PA and receiving rEPO therapy (N = 15) had IgG anti-PA responses comparable to that of those not receiving rEPO therapy (N = 15). In contrast, in the patients immunized with TT, those receiving rEPO (N = 15) developed significantly higher IgG anti- TT levels than those not receiving rEPO (N = 14) (time-group interaction P =0.005). The peak difference between these groups wits at two weeks, where the rEPO-treated patients developed a 4.1-fold mean increase in IgG anti-TT level and those not receiving rEPO developed only a 1.4-fold mean increase in IgG anti-TT level (P < 0.01). The difference in immune response to TT in the rEPO compared to the non-rEPO-treated patients could not be explained by differences between the groups in any of the parameters measured at baseline or during the post-immunization period. In conclusion, rEPO therapy increased immune response to TT but not PA, which suggests that rEPO enhances immune response to T cell dependent antigens.

UR - http://www.scopus.com/inward/record.url?scp=0029832432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029832432&partnerID=8YFLogxK

M3 - Article

C2 - 8840284

AN - SCOPUS:0029832432

VL - 50

SP - 543

EP - 549

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -